- Author's Reply
-
Hiraoka S, Kato J, Okada H
- KMID: 2417688
- Intest Res.
- 2018 Apr;16(2):321-322.
- doi: 10.5217/ir.2018.16.2.321
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics of Esophageal Motility Disorders in Patients With Heartburn
-
Takahashi S, Matsumura T, Kaneko T, Tokunaga M, Oura H, Ishikawa T, Nagashima A, Shiratori W, Akizue N, Ohta Y, Kikuchi A, Fujie M, Saito K, Okimoto K, Maruoka D, Nakagawa T, Arai M, Kato J, Kato N
- KMID: 2521155
- J Neurogastroenterol Motil.
- 2021 Oct;27(4):545-554.
- doi: 10.5056/jnm20131
Background/Aims Esophageal motility disorders (EMDs) contribute to the pathophysiology of gastroesophageal reflux disease. However, the causes of EMDs and their impact on gastroesophageal reflux disease-associated symptoms remain unknown. This study aims... -
- CITED
-
- Close
- SHARE
-
- Close
- Switching to systemic therapy after locoregionaltreatment failure: Definition and best timing
-
Ogasawara , Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi , Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N
- KMID: 2500378
- Clin Mol Hepatol.
- 2020 Apr;26(2):155-162.
- doi: 10.3350/cmh.2019.0021n
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE... -
- CITED
-
- Close
- SHARE
-
- Close
- Quality Indicators for the Detection of Helicobacter pylori-Negative Early Gastric Cancer: A Retrospective Observational Study
-
Ishibashi F, Kobayashi K, Fukushima K, Tanaka R, Kawakami T, Kato J, Sugihara K
- KMID: 2511229
- Clin Endosc.
- 2020 Nov;53(6):698-704.
- doi: 10.5946/ce.2019.203
Background/Aims: While Helicobacter pylori (HP)-negative gastric cancer is frequently reported, little is known about the predictors for detecting HP-negative early gastric cancer (EGC). We aimed to evaluate the predictors for... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium
-
Karasawa Y, Kato J, Kawamura S, Kojima K, Ohki T, Seki M, Tagawa K, Toda N
- KMID: 2518464
- Gut Liver.
- 2021 Jul;15(4):616-624.
- doi: 10.5009/gnl20214
Background/Aims: Acute cholangitis (AC) is a potentially life-threatening bacterial infection, and timely antimicrobial treatment, faster than that achieved with bacterial cultures, is recommended. Although the current guidelines refer to empirical antimicrobial... -
- CITED
-
- Close
- SHARE
-
- Close
- Rapid On-Site Evaluation by Endosonographers during Endoscopic Ultrasonography-Guided Fine-Needle Aspiration for Diagnosis of Gastrointestinal Stromal Tumors
-
Tamura T, Yamashita , Ueda K, Kawaji Y, Itonaga M, Murata SI, Yamamoto K, Yoshida T, Maeda H, Maekita T, Iguchi M, Tamai H, Ichinose M, Kato J
- KMID: 2389243
- Clin Endosc.
- 2017 Jul;50(4):372-378.
- doi: 10.5946/ce.2016.083
BACKGROUND/AIMS: Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has been used to diagnose gastrointestinal submucosal tumors (SMTs). Although rapid on-site evaluation (ROSE) has been reported to improve the diagnostic accuracy of EUS-FNA... -
- CITED
-
- Close
- SHARE
-
- Close
- The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
-
Taki S, Tamai H, Ida Y, Shingaki N, Kawashima , Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2404722
- Gut Liver.
- 2018 Jan;12(1):86-93.
- doi: 10.5009/gnl17048
BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?
-
Kato J, Hiraoka S, Nakarai A, Takashima , Inokuchi T, Ichinose M
- KMID: 2174504
- Intest Res.
- 2016 Jan;14(1):5-14.
- doi: 10.5217/ir.2016.14.1.5
Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity,... -
- CITED
-
- Close
- SHARE
-
- Close
- Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis
-
Hiraoka S, Inokuchi T, Nakarai A, Takashima , Takei D, Sugihara Y, Takahara M, Harada K, Okada H, Kato J
- KMID: 2429068
- Gut Liver.
- 2018 Mar;12(2):142-148.
- doi: 10.5009/gnl17013
BACKGROUND/AIMS: Both fecal immunochemical test (FIT) and fecal calprotectin (Fcal) results are useful biomarkers for ulcerative colitis (UC). However, the situations in which each marker should be used are largely... -
- CITED
-
- Close
- SHARE
-
- Close
- An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
-
Nakarai A, Kato J, Hiraoka S, Takashima , Inokuchi T, Takahara M, Sugihara Y, Harada K, Okada H
- KMID: 2417308
- Gut Liver.
- 2018 Jul;12(4):420-425.
- doi: 10.5009/gnl17236
BACKGROUND/AIMS: Although mucosal healing (MH) has been considered a treatment goal for patients with ulcerative colitis (UC), the risk factors predictive of relapse in patients who achieve MH are unknown.... -
- CITED
-
- Close
- SHARE
-
- Close
- Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis
-
Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M
- KMID: 2434160
- Intest Res.
- 2018 Oct;16(4):579-587.
- doi: 10.5217/ir.2018.00021
BACKGROUND/AIMS: In clinical practice, colonoscopy has been regarded as the gold standard for the evaluation of disease severity as well as mucosal healing in ulcerative colitis (UC). Some activity indices... -
- CITED
-
- Close
- SHARE
-
- Close
- The Wire-Grasping Method as a New Technique for Forceps Biopsy of Biliary Strictures: A Prospective Randomized Controlled Study of Effectiveness
-
Yamashita , Ueda K, Kawaji Y, Tamura T, Itonaga M, Yoshida T, Maeda H, Magari H, Maekita T, Iguchi M, Tamai H, Ichinose M, Kato J
- KMID: 2412055
- Gut Liver.
- 2016 Jul;10(4):642-648.
- doi: 10.5009/gnl15231
BACKGROUND/AIMS: Transpapillary forceps biopsy is an effective diagnostic technique in patients with biliary stricture. This prospective study aimed to determine the usefulness of the wire-grasping method as a new technique... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
-
Hiraoka S, Takashima , Kondo Y, Inokuchi T, Sugihara Y, Takahara M, Kawano S, Harada K, Kato J, Okada H
- KMID: 2402650
- Intest Res.
- 2018 Jan;16(1):75-82.
- doi: 10.5217/ir.2018.16.1.75
BACKGROUND/AIMS: The efficacy of anti-tumor necrosis factor α (anti-TNFα) antibodies for postoperative Crohn's disease (CD) in patients who were treated with these agents prior to surgery is largely unknown. METHODS: CD... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
-
Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima , Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 2412052
- Gut Liver.
- 2016 Jul;10(4):617-623.
- doi: 10.5009/gnl15193
BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using... -
- CITED
-
- Close
- SHARE
-
- Close
- The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces
-
Hiraoka S, Takashima , Inokuchi T, Nakarai A, Takahara M, Harada K, Seki Y, Watanabe K, Kato J, Okada H
- KMID: 2449961
- Intest Res.
- 2019 Apr;17(2):202-209.
- doi: 10.5217/ir.2018.00086
BACKGROUND/AIMS: Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of a Null Response to Pegylated Interferon alpha-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
-
Wada Y, Tamai H, Kawashima , Shingaki N, Mori Y, Kawaguchi , Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 1792366
- Gut Liver.
- 2014 Jul;8(4):421-427.
BACKGROUND/AIMS: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon alpha-2b plus ribavirin therapy in patients... -
- CITED
-
- Close
- SHARE
-
- Close
